The Advanced Research Projects Agency for Health (ARPA-H) has appointed Etta D. Pisano, MD, FACR, senior portfolio lead, to build the agency’s clinical trial portfolio and lead the ARPA-H Advancing Clinical Trials Readiness Initiative under ARPA-H Resilient Systems Mission Office Director Jennifer Roberts. The first radiologist to be appointed to such a role, Dr. Pisano is an internationally recognized expert in women’s health, breast cancer research, and the use of artificial intelligence in medical imaging applications. Dr. Pisano will continue to serve as study chair of the large-scale Tomosynthesis Mammographic Imaging Screening Trial (TMIST) for the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN). TMIST is led by ECOG-ACRIN with funding from the National Cancer Institute, part of the National Institutes of Health. She will also continue to serve as the American College of Radiology® (ACR®) Chief Research Officer (CRO). Dr. Pisano previously… 

Forscher haben ein neues, interpretierbares Modell der künstlichen Intelligenz (KI) entwickelt, um das 5-Jahres-Brustkrebsrisiko anhand von Mammographien vorherzusagen. Dies geht aus einer neuen Studie hervor, die heute in Radiology , einer Zeitschrift der Radiological Society of North America, veröffentlicht wurde ( RSNA ). Nach Angaben der American Cancer Society erkrankt eine von acht Frauen oder etwa 13 % der weiblichen Bevölkerung in den USA im Laufe ihres Lebens an invasivem Brustkrebs und eine von 39 Frauen (3 %) wird an dieser Krankheit sterben. Für viele Frauen ist die Brustkrebsvorsorge mittels Mammographie die beste Möglichkeit, Brustkrebs frühzeitig zu erkennen, wenn die Behandlung am effektivsten ist. Regelmäßige Mammographien können das Risiko, an Brustkrebs zu sterben, deutlich senken. Es bleibt jedoch unklar, wie sich allein durch das Screening genau vorhersagen lässt, welche Frauen Brustkrebs entwickeln werden. https://pubs.rsna.org/journal/radiology

Magnetic resonance imaging (MRI) and lumbar puncture (LP) may not always be necessary for diagnosing and managing a serious neurological complication associated with CAR T-cell therapy, according to a new Blood Advances study. Findings further validated the use of the electroencephalogram (EEG) – a noninvasive test measuring electrical activity in the brain – in managing this neurotoxicity. Authors sought to evaluate the necessity of three diagnostic tests used to manage care for recipients of CAR T-cell therapy experiencing immune effector cell-associated neurotoxicity syndrome (ICANS). While ICANS’ underlying mechanisms are not entirely understood, patients with ICANS may experience a range of neurological symptoms, including confusion, tremors, seizures, and, in rare cases, serious brain swelling and comas.